Kornimate/medical-research-clean huggingface dataset:
effectiveness of character strengths-based intervention among breast cancer patients

Conditions: Breast Cancer

Summary: the research design is a randomized control trial to evaluate the effectiveness of character strengths-based intervention in enhancing self-esteem, quality of life and alleviating depression in breast cancer patients. the type of intervention is psychological intervention. participants in the intervention group will receive character strengths-based intervention. participants in the control group will receive placebo control care.

the character strengths-based intervention may could enhance self-esteem, quality of life and alleviate depression, but the placebo control care did not do so. strengths use is indeed associated with elevated levels of life satisfaction and quality of life. it is positively related to self-esteem and leads to greater self-esteem over time. moreover, strengths use could help decrease depression in the patients, and has beneficial effect on quality of life. there is a model that examined the mechanism of how strengths use related to enhanced self-esteem, happiness and life satisfaction. individuals who use their strengths and experience greater levels of life satisfaction is mediated by self-esteem and depression. preliminary evidence suggested that character strengths-based intervention has positive impact on psychological well-being include improving self-esteem among women with breast cancer in spain. however, there is a worldwide paucity of rigorous trials that have evaluated the effectiveness of character strengths-based interventions for breast cancer patients.

Eligibility criteria:
inclusion criteria: * have a confirmed diagnosis of breast cancer; * aged above 18 years old; * native chinese and proficient in oral mandarin communication; * agree to participate in the study and offer a written informed consent regarding their voluntary; * are able to comprehend and complete the questionnaires independently. exclusion criteria: * suffering from other or multiple life-threatening diseases; * psychosis (for example, delusional disorder, schizophrenia); * having participated in any type of group or individual psychological intervention in the past half year.

Keywords: self-esteem quality of life depression
the current health status of patients living with type 1 diabetes from the lmc diabetes patient registry

Conditions: Type1diabetes

Summary: this retrospective study uses the canadian lmc diabetes registry to describe the current health status of canadians with type 1 diabetes. the study provides a detailed report of the demographic composition, treatment regimens, self-care approaches, health status, metabolic outcomes, and glycemic control of a large canadian community-based, specialist-led cohort of patients with type 1 diabetes. specific study outcomes will also be evaluated in a subgroup of patients using continuous subcutaneous insulin infusion (csii) therapy.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of type 1 diabetes for ≥ 6 months * assessed by an lmc endocrinologist between july 1, 2015 and june 30, 2018 * followed by an lmc endocrinologist for \> 6 months * informed consent provided and signed for medical record data to be used for research purposes exclusion criteria: * clinical diagnosis of type 2 diabetes

Keywords: diabetes mellitus, type 1 hypoglycemia hemoglobin a1c time in range continuous glucose monitor
postoperative pain in children aged from 3 to 5 years following full mouth dental rehabilitation under general anesthesia. a cross-sectional study. rehabilitation under general anesthesia

Conditions: Post-operative Pain

Summary: the purpose of this study is monitoring postoperative pain in children aged from 3 to 5 years following full mouth dental rehabilitation under general anesthesia

the study's investigators will record all data related to the immediate postoperative period during the child's stay in the post anesthetic recovery room (par). just prior to discharge home, the child's discomfort will be measured using face, legs, activity, cry, and consolability pain assessment tool (flacc). postoperative data is collected by the same investigator who contacted caregivers by phone at 4 postoperative times: 1, 3, 7, and 30 days after the drga using the dental questionnaire. when a participant cannot be reached on the scheduled day, the information is collected on the nearest subsequent day. the postoperative assessment included: the questioner and an inquiry about the use of medications; the child's ability to eat a regular diet; and "mouth-related" complaints other than dental discomfort. dental discomfort is assessed in this study by 2 scales: the flacc (table 1) and the dental questioner (table 2). flacc pain assessment tool. the flacc scale was originally developed to quantify postoperative pain in infants from 2 months old to children up to 7-years-old.(7) this scale assesses 5 aspects of behavior: (f) facial expression; (l) leg movement; (a) activity; (c) cry; and (c) consolability. the range for the total score is from 0 (no pain) to 10 (intense pain). the examiner is standardized to use of the flacc by a par nurse who was experienced in scoring pain with this scale. the dental questioner. the questionnaire covered the following items: did the child have pain, bleeding from dental origin, sore throat, fever, vomiting, inability to eat, sleepiness, drowsiness, cough, nausea or psychological changes?

Eligibility criteria:
inclusion criteria: * egyptian dental children undergoing full mouth dental rehabilitation under general anesthesia (3-5 years old ) * children selected from pediatric dentistry and dental public health department faculty of dentistry cairo university * children with no developmental delay. * children with normal physical status. * parents who can be communicated well exclusion criteria: * parents refusing participation in the study. * parents who cannot be communicated well * children with developmental abnormalities

Keywords: general anesthesia, clinical manifestations. .
treatment of keratoconus with palk versus pk

Conditions: Keratoconus

Summary: the purpose of this study is to evaluate the visual results of patients with keratoconus treated with one of two techniques: penetrating keratoplasty (pk) vs. pachymetry and excimer laser assisted lamellar keratoplasty (palk).


Eligibility criteria:
inclusion criteria: * diagnosis of keratoconus grades iii or iv in the amsler krumeich classification. * need of surgical procedure * no endothelial scar * best corrected visual acuity \<20/40 * contact lens intolerance * imagenological map pachymetric acquisition over 90% at 9 mm corneal diameter exclusion criteria: * contraindication for any of the techniques evaluated. * requiring additional surgical procedures. * diagnostic of other ectasia that were not primary keratoconus.

Keywords: keratoconus
inhaled sedation using the anesthetic-conserving device ( anaconda) in prehospital emergency medecine.

Conditions: Endotracheal Intubation; Deep Sedation

Summary: achieving the optimal sedation level for patient management is not always possible using our standard intravenous medications in pre-hospital emergency medicine. inhaled sedation is possible with the anesthetic-conserving device with a standard respirator. the pharmacodynamics and pharmacokinetics of halogenated agents allow deep sedation quickly after absorption. the feasibility of inhaled sedation has never been studied in hospital.

retrospecive clinical monocentric study with sedated ventilated patients with isoflurane with the anaconda® system out of hospital.

Eligibility criteria:
inclusion criteria: * patient sedated by isoflurane with anesthetic-conserving device in pre-hospital * major patient * not opposed to participating exclusion criteria: * adults under legal protection * patient refusal to participate in study
study of ak119 and ak112 with or without chemotherapy for nsclc patients

Conditions: NSCLC

Summary: this is a phase ib/ii study to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of ak119 and ak112 with or without chemotherapy for nsclc patients.


Eligibility criteria:
inclusion criteria: 1. be able to understand and voluntarily sign the written informed consent, which must be signed before the designated research procedure. 2. age ≥ 18 and ≤ 75, male or female. 3. local advanced or metastatic non-squamous nsclc confirmed by histology or cytology according to eighth edition of the tnm classification for lung cancer. 4. egfr activating mutation confirmed by tumor histology, cytology or hematology. 5. failed to previous egfr-tki treatment. 6. ecog performance status 0 to1. 7. life expectancy ≥3 months. 8. at least one measurable lesion according to recist v1.1. 9. adequate organ function. exclusion criteria: 1. histological or cytological pathology confirmed the presence of small cell carcinoma or squamous cell carcinoma. 2. have suffered from the second primary active malignant tumor in the past 3 years. 3. there are other driving gene mutations that can obtain effective treatment. 4. receipt of the following treatments or procedures: immunotherapy, including immunocheckpoint inhibitors, immunocheckpoint agonists, immunocellular therapy, and any other treatment targeting tumor immune mechanism; systematic chemotherapy in the advanced stage (iiib-iv); anti-angiogenesis drugs, except for small molecule anti-angiogenesis drugs with drug withdrawal more than 4 weeks; extensive radiotherapy within 4 weeks; egfr-tkis within 2 weeks. 5. symptomatic central nervous system metastases. 6. the toxicity of previous anti-tumor therapy has not been alleviated. 7. uncontrolled massive ascites, pleural effusion or pericardial effusion. 8. active autoimmune diseases in the past 2 years. 9. history of interstitial lung disease or noninfectious pneumonitis. 10. suffering from clinically significant cardiovascular or cerebrovascular diseases. 11. history of severe bleeding tendency or coagulation dysfunction. 12. history of deep vein thrombosis, pulmonary embolism or any other serious thromboembolism in the past 3 months. 13. serious infection in the past 4 weeks. 14. acute exacerbation of chronic obstructive pulmonary disease or asthma in the past 4 weeks. 15. history of human immunodeficiency virus (hiv) infection. 16. history of severe hypersensitivity reactions to other mabs. 17. history of organ transplantation. 18. any other conditions that, in the opinion of the investigator, may increase the risk when receiving the investigational product.
assessment of proactive treatments in patients with wet age-related macular degeneration (wamd) which have never undergone treatment of this particular disease

Conditions: Wet Age-related Macular Degeneration

Summary: in this observational study researchers want to learn more about changes in visual acuity (clarity of vision) with proactive flexible treatments over time in patients suffering from wet age-related macular degeneration (wamd) after decision to treat with aflibercept (eylea) was made. wet amd is an eye disease that progressively destroys the macula, the central portion of the retina, impairing central vision.


Eligibility criteria:
inclusion criteria: * a diagnosis of wamd. * patients for whom the decision to initiate treatment with ivt aflibercept in a proactive regimen was made as routine clinical practice. * treatment-naïve in the study eye (no prior therapy for wamd). * patient age ≥50 years of age. * written informed patient consent before the start of data collection (according to the requirements of the local authorities and laws). exclusion criteria: * participation in an investigational program with interventions outside of routine clinical practice. * patients with contraindications to ivt aflibercept listed in the local marketing authorization. * planned treatment regimen outside of the local marketing authorization. * patients with eye diseases, e.g. advanced glaucoma or visually significant cataracts, likely to require surgery during the observation period in the study eye. * concomitant ocular or systemic administration of drugs up to 3 months before ivt aflibercept treatment that could interfere with or potentiate the mechanism of action of ivt aflibercept, including other anti-vegf agents in the fellow eye. * any other retinal disease which may interfere with the treatment of wamd.
genotype/phenotype correlation of movement disorders and other neurological diseases

Conditions: Movement Disorders; Myoclonus; Nervous System Diseases; Tic Disorders; Tremor

Summary: the purpose of this protocol is to identify families with inherited neurologic conditions, especially movement disorders, to evaluate affected and unaffected individuals clinically, and to obtain blood samples for genetic analysis.

the purpose of this protocol is to identify families with inherited neurologic conditions, especially movement disorders, to evaluate affected and unaffected individuals clinically, and to obtain blood samples for genetic analysis.

Eligibility criteria:
neurologic disease or movement disorders affecting 2 or more family members. no conditions in which phlebotomy is contra-indicated.

Keywords: family studies genetic myoclonus tics tremor movement disorders neurological disease
radiation therapy in treating patients who are undergoing surgery to remove a metastatic brain tumor

Conditions: Metastatic Cancer

Summary: rationale: specialized radiation therapy that delivers radiation directly to the area where a tumor was surgically removed may kill any remaining tumor cells and cause less damage to normal tissue. purpose: this phase i/ii trial is studying radiation therapy to see how well it works in treating patients who are undergoing surgery to remove a metastatic brain tumor.

objectives: primary * determine the 1-year local control rate in patients undergoing resection of a solitary brain metastasis comprising intraoperative radiotherapy using the intrabeam® system. secondary * determine the survival of patients treated with this therapy. * determine distant recurrence of disease in patients treated with this therapy. * determine the toxicity of this therapy in these patients. * determine the quality of life of patients treated with this therapy. outline: this is a nonrandomized study. patients undergo surgical resection of a brain metastasis. patients then undergo intraoperative radiotherapy using the intrabeam® system. quality of life is assessed at baseline and then every 3 months for 2 years. patients are followed within 48 hours after surgery, at 1 and 3 months, and then every 3 months for 2 years. projected accrual: a total of 31-62 patients will be accrued for this study.

Eligibility criteria:
disease characteristics: * newly diagnosed supratentorial solitary brain metastasis by enhanced mri or ct scan * resectable disease * histological evidence of metastatic carcinoma by intraoperative pathology * no primary lymphoma, germ cell carcinoma, or small cell lung cancer patient characteristics: age * 18 and over performance status * karnofsky 70-100% life expectancy * at least 3 months hematopoietic * not specified hepatic * not specified renal * not specified cardiovascular * no uncontrolled hypertension * no unstable angina pectoris * no uncontrolled dysrhythmias other * not pregnant or nursing * negative pregnancy test * fertile patients must use effective contraception * no serious infection * no other medical illness that would preclude study participation prior concurrent therapy: biologic therapy * not specified chemotherapy * no prior temozolomide or polifeprosan 20 with carmustine implant (gliadel® wafer) for brain metastasis endocrine therapy * not specified radiotherapy * no prior brain radiotherapy of any kind, including local or whole brain external beam radiotherapy, brachytherapy, or stereotactic radiosurgery * no concurrent external beam radiotherapy to the brain * not planning adjuvant whole brain radiotherapy after study therapy surgery * not specified other * no other prior conventional or investigational local or systemic agents for brain metastasis

Keywords: tumors metastatic to brain
risk factors in tachycardiomyopathy

Conditions: Atrial Fibrillation; Atrial Flutter; Ventricular Premature Complexes

Summary: decision between rate control and rhythm control can be a challenge in clinical practice. while there is some guiding evidence, we still lack a comprehensive insight into different subgroups of patients that will benefit from a rhythm control treatment. empathy is a prospective clinical study in patients presenting with heart failure and a tachyarrhythmic rhythm disturbance. biomarkers, routinely obtained results from clinical examinations, and results from endomyocardial biopsies shall be evaluated to identify patients which have better outcome from a rhythm control strategy by ablation therapy or, if contraindicated by pharmacological rhythm control. this study is designed to identifying risk factors and subgroups profiting from rhythm restoration and therefore improve current therapeutic approaches and the rate of recurrence-free survival.


Eligibility criteria:
inclusion criteria: * newly diagnosed left ventricular ejection fraction ≤ 50% * endomyocardial biopsy available * tachycardic rhythm disturbance with a rhythm control strategy planned for tachycardic atrial fibrillation or flutter (≥100/min) or more than 10000 ventricular premature beats in 24 hours exclusion criteria: * age \<18 years * patient unable or unwilling to give informed consent * coronary artery stenosis \>50% * relevant valvular disease * simultaneous contraindications against amiodarone treatment and pulmonary vein isolation/ablation therapy * present or suspected alcohol/drug dependency will result in exclusion from the study

Keywords: tachycardiomyopathy atrial fibrillation emid (enrichment of mitochondria at the intercalated discs) biopsy empathy
spontaneous breathing trials using pressure-support or t-tube in chronic obstructive pulmonary disease patients weaning mechanical ventilation

Conditions: Weaning of Mechanical Ventilation; Chronic Obstructive Pulmonary Disease

Summary: weaning of mechanical ventilation (mv) is an essential part in management of patients with chronic obstructive pulmonary disease (copd) when critically ill. the best strategy to be used has not been established. objective: to compare the spontaneous breathing trial (sbt) in pressure support ventilation with sbt through "t" tube in weaning of mv in patients with copd. design: randomized clinical trial. methods: this study will include patients with copd, admitted to the intensive care unit of hospital nossa senhora da conceição, undergoing mv for at least 48 hours. when considered by the care team ready for sbt, they will be randomized to one of the following strategies: sbt in pressure support or sbt through "t" tube. the primary endpoint of this study will be the reduction in the days spent on mv. other outcomes measured will be mortality, extubation and success rate, time to weaning of mv, length of icu stay and incidence of tracheostomy.


Eligibility criteria:
inclusion criteria: * copd patients admitted to our icu for acute respiratory failure, submitted to mechanical ventilation for at least 48 hours * 18 years or older exclusion criteria: * tracheostomy * younger than 18 years * refuse to give informed consent * individuals who are already enrolled in another clinical trial

Keywords: weaning chronic obstructive pulmonary disease spontaneous breathing trial
intermediate and long-term efficacy of endovascular treatment for tasc c&d aortoiliac occlusive disease

Conditions: Peripheral Arterial Disease

Summary: this is a prospective, multicenter, real-world, registry study, which aims to observe the intermediate and long-term efficacy of different endovascular treatments for tasc c\&d aortoiliac occlusive disease.

currently, the optimal therapy for tasc c and d type aortic occlusive disease is still controversial. the evidence comes from several singe-center studies with small sample size. in addition, the long-term efficacy of stent implantation and drug coated device in aortic occlusive disease remains unclear, which might be affected by the type of stent and calcification extent. thus, this study aims to observe the intermediate and long-term efficacy of different endovascular treatments for tasc c\&d aortoiliac occlusive disease in multiple centers.

Eligibility criteria:
inclusion criteria: * rutherford classification of 3-6 * willing to comply with all follow-up evaluations at the specified times * target lesion(s) located within the native infrarenal abdominal aorta and/or common iliac artery and/or external iliac artery * evidence of ≥ 50% stenosis, restenosis (from pta or adjunct therapy, not including stents or stent grafts), or occlusion of target lesion(s), or arterial thrombosis underwent pmt or cdt * provides written informed consent exclusion criteria: * contraindication or known untreatable allergy to antiplatelet therapy, anticoagulants, thrombolytic drugs, or any other drug used during the study * known hypersensitivity to contrast material that cannot be adequately pretreated * bleeding diathesis or coagulopathy, known hypercoagulable condition or refuses blood transfusion * female currently breastfeeding, pregnant, or of childbearing potential not using adequate contraceptive measures * life expectancy less than 24 months * current participation in an investigational drug or other device study * severe comorbid conditions * myocardial infarction or stroke within 3 months prior to enrollment
physical activity in transfusion dependent patients with myelodysplastic syndrome

Conditions: Myelodysplastic Syndromes

Summary: this study assesses feasibility and patient acceptability of using a fitbit to monitor step count and heart rate in transfusion dependent patients with myelodysplastic syndrome. information from this study may help researchers understand if there is any correlation between activity level and anemia.

this study assesses feasibility and patient acceptability of using a fitbit to monitor step count and heart rate in transfusion dependent patients with myelodysplastic syndrome. information from this study may help researchers understand if there is any correlation between activity level and anemia.

Eligibility criteria:
inclusion criteria: * confirmed pathologic diagnosis of mds * requiring \>= 2 blood transfusions in the past month if previously diagnosed or hemoglobin =\< 8 g/dl if newly diagnosed * age \>= 18 * eastern cooperative oncology group (ecog) performance status of 0 to 2 * ambulatory (use of a walking aid, such as a cane or rollator, is acceptable) * able to give informed consent * willing to comply with all study procedures and available for the duration of the study * able to read and/or understand english * have access to an iphone 4s or later, ipad 3 generation or later, android 5.0 or later, or windows 10 device * have access to bluetooth low energy (le) and internet connection for syncing exclusion criteria: • uncontrolled illness including, but not limited to, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements